Pharmacovigilance organizations are under pressure from every direction. Global adverse event case volumes have grown dramatically with the expansion of post-market safety surveillance requirements under FDA and EMA regulations, while the complexity of biologics and specialty drug safety profiles demands increasingly sophisticated medical evaluation. The risk is that highly trained drug safety scientists and physicians spend significant time on administrative case processing tasks that don't require their expertise. A pharmacovigilance company virtual assistant addresses that mismatch directly.
Adverse Event Case Volumes Are Rising
The FDA's MedWatch database received over 2 million adverse event reports in fiscal year 2023, and voluntary and mandatory reporting volumes continue to climb as post-market safety requirements expand under FDA Amendments Act provisions and EMA's strengthened pharmacovigilance framework. For pharmacovigilance service companies and in-house safety departments alike, case intake volumes often exceed the processing capacity of dedicated safety teams during peak periods — particularly following product launches, safety label changes, or major conference-driven patient awareness campaigns.
A pharmacovigilance virtual assistant manages the intake layer of case processing:
- Case receipt and acknowledgment: Logging incoming adverse event reports from all channels — call centers, medical information lines, literature sources, and spontaneous reporter submissions — with date and time stamps that anchor regulatory clock start times
- Regulatory timeline tracking: Maintaining case processing dashboards that flag expedited 7-day and 15-day reporting deadlines (ICSRs to FDA and EMA) so safety teams never approach a regulatory deadline unaware
- Case data entry preparation: Transferring reporter information, suspect product details, and adverse event narratives from intake forms into safety database templates (Argus, ARISg, Oracle AERS) for safety scientist review
- Literature monitoring support: Scanning designated safety literature sources and flagging articles containing potential adverse event reports for safety physician review and case creation
Supporting Signal Detection Workflows
Pharmacovigilance signal detection requires systematic data aggregation and analysis. A virtual assistant supports the preparatory work that feeds signal detection processes:
- Aggregate case compilation: Pulling case line listings by product, event term, and reporting period for quarterly signal review meetings
- PSUR and DSUR documentation coordination: Gathering data inputs from regulatory, clinical, and medical teams for Periodic Safety Update Reports and Development Safety Update Reports, tracking section completion against submission deadlines
- Health authority query management: Logging incoming health authority queries, routing to the responsible safety officer, and tracking response deadline compliance
The Council for International Organizations of Medical Sciences (CIOMS) has noted in its working group publications that administrative efficiency in pharmacovigilance case processing is a critical determinant of a company's ability to meet expedited reporting obligations — particularly for small and mid-size drug companies with lean safety teams.
Risk Minimization Program Administration
Beyond case processing, pharmacovigilance departments often manage Risk Evaluation and Mitigation Strategy (REMS) programs that include patient enrollment registries, healthcare provider certifications, and pharmacy authorization programs. A virtual assistant supports REMS administration by maintaining enrollment records, tracking certification renewal timelines, and coordinating with REMS vendors on data reconciliation.
FDA data shows that REMS programs cover more than 60 products across therapeutic areas including oncology, psychiatry, and reproductive medicine — each requiring consistent administrative attention that a dedicated VA can provide.
Ensuring Regulatory Compliance Through Administrative Precision
Regulatory clock errors — incorrect case receipt dates, missed expedited report windows, or improperly categorized seriousness assessments — can trigger FDA Form 483 observations and warning letters with serious business consequences. A pharmacovigilance virtual assistant who owns the intake and tracking layer adds a systematic check that reduces the risk of administrative compliance failures reaching the regulatory submission stage.
To add that administrative precision to your pharmacovigilance operations, Stealth Agents provides virtual assistants trained in safety case processing workflows and regulatory timeline management.
Sources
- U.S. Food and Drug Administration — MedWatch Adverse Event Reporting System Annual Statistics
- European Medicines Agency (EMA) — Pharmacovigilance Legislation and Guidelines
- Council for International Organizations of Medical Sciences (CIOMS) — Working Group Reports on Pharmacovigilance
- ICH E2E — Pharmacovigilance Planning Guideline